Robust remission metrics and TSLP molecular pathway inhibition
Detailed late-stage clinical data released on Tuesday confirmed that the monoclonal antibody Tezspire (tezepelumab) achieved primary clinical endpoints with high statistical significance among patients afflicted with uncontrolled, symptomatic eosinophilic esophagitis. Following 24 weeks of active administration, 65% of patients in the 210 mg cohort and 69% of individuals receiving the 420 mg dosage achieved complete histological remission, compared to merely 3.5% within the placebo control arm.
Crucially, the therapeutic advantages demonstrated long-term durability through 52 continuous weeks, with sustained remission verified in 67.8% of patients on the 210 mg regimen and 63.3% on the 420 mg regimen, versus 5.4% receiving placebo.
















